Günther G. Steger

TL;DR: One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

TL;DR: Adjuvant denosumab 60 mg twice per year reduces the risk of clinical fractures in postmenopausal women with breast cancer receiving aromatase inhibitors, and can be administered without added toxicity.

TL;DR: A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.

TL;DR: The results of the primary analysis constitute Level 1 evidence for clinical validity of the PAM50 test for predicting the risk of DR in postmenopausal women with ER+ EBC, and a 10-year metastasis risk of <3.5% makes it unlikely that additional chemotherapy would improve this outcome.

TL;DR: The final results from ABCSG 12 suggest that twice-yearly ZOL enhances the efficacy of adjuvant endocrine treatment, and this benefit is maintained long-term.